VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors

Figure 8 Correlation between VCAN and tumor microenvironment score, tumor mutation burden, or immune checkpoint genes. A: Tumor purity of low VCAN group and high VCAN group; B: Stromal score, immune score, and ESTIMATE score of low VCAN group and high VCAN group; C: Significant VCAN-related immune checkpoint genes (r > 0.3, P < 0.05); D: Tumor mutation burden of low VCAN group and high VCAN group; E: Correlation between VCAN and programmed cell death protein 1/cytotoxic T lymphocyte antigen 4. ^cP < 0.001. TME: Tumor microenvironment.